Other clinically important peanut allergen epitopes

Other clinically important peanut allergen epitopes refers to the specific molecular regions of peanut proteins beyond the primary major allergens Ara h 1, Ara h 2, and Ara h 3. This category includes potent allergens such as Ara h 6, which shares significant structural homology and clinical relevance with Ara h 2, as well as Ara h 8 (a PR-10 protein) and Ara h 9 (a lipid transfer protein) (WHO/IUIS Allergen Nomenclature, 2023). These epitopes are the molecular sites recognized by immunoglobulin E (IgE) antibodies in sensitized individuals, leading to the cross-linking of FcεRI receptors on mast cells and basophils. This interaction triggers the release of histamine and other mediators, resulting in clinical symptoms ranging from mild urticaria to life-threatening anaphylaxis (Bublin & Breiteneder, 2014). In the context of drug development, these epitopes are targeted by various forms of immunotherapy, including oral immunotherapy (OIT) products like Palforzia, which utilize whole peanut protein to induce desensitization (FDA, 2020). Additionally, emerging peptide-based immunotherapies, such as PVX108, utilize specific T-cell epitopes from these proteins to promote tolerance without the risk of IgE-mediated anaphylaxis (Prickett et al., 2015). Monoclonal antibodies like omalizumab are also used to prevent IgE from binding to these epitopes, thereby mitigating the allergic response.

Other names

Minor peanut allergen epitopesAra h 6 epitopesAra h 8 epitopesAra h 9 epitopesNon-major peanut allergen componentsAra h 4-17 epitopes

Induction of immunological tolerance and desensitization through controlled exposure to allergen epitopes (immunotherapy), or the prevention of IgE-mediated mast cell activation via monoclonal antibody sequestration of IgE or modulation of Th2 inflammatory pathways.